Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: A preliminary report

Cardiovascular Diabetology

Volumn 8, Issue , 2009, Pages

  Valdivielso, Pedro ^a   Rioja, José ^a   García Arias, Carlota ^a   Sánchez Chaparro, Miguel Angel ^a   González Santos, Pedro ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; FLUINDOSTATIN; GLICLAZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; METFORMIN; OMEGA 3 FATTY ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLYCOSYLATED HEMOGLOBIN; INDOLE DERIVATIVE; LIPID; MONOUNSATURATED FATTY ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET THERAPY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENING DOSAGE; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; DRUG COMBINATION; FAMILIAL HYPERLIPEMIA; GLUCOSE BLOOD LEVEL; LOW CALORY DIET; MIDDLE AGED; MULTIMODALITY CANCER THERAPY;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; APOLIPOPROTEIN B-48; BLOOD GLUCOSE; BLOOD PRESSURE; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERTENSION; HYPOGLYCEMIC AGENTS; INDOLES; LIPIDS; MALE; MIDDLE AGED;

EID: 60649094541     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-8-1     Document Type: Article

References (23)

1. Taskinen M Diabetic dyslipidaemia: From basic research to clinical practice* Diabetologia 2003, 46(6):733-749 10.1007/ s00125-003-1111-y 12774165
2. Grundy SM Cleeman JI Merz CNB Brewer HBJ Clark LT Hunninghake DB Pasternak RC Smith SCJ Stone NJ for the Coordinating Committee of the National Cholesterol Education Program, Endorsed by the National Heart, Lung and Blood Institute American College of Cardiology Foundation and American Heart Association Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 2004, 110(2):227-239 10.1161/ 01.CIR.0000133317.49796.0E 15249516
3. Proctor SD Mamo JC Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits Arterioscler Thromb Vasc Biol 2003, 23(9):1595-1600 10.1161/ 01.ATV.0000084638.14534.0A 12842838
4. Lopez-Miranda J Williams C Lairon D Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism Br J Nutr 2007, 98(3):458-473 10.1017/S000711450774268X 17705891
5. Nakano T Nakajima K Niimi M Fujita MQ Nakajima Y Takeichi S Kinoshita M Matsushima T Teramoto T Tanaka A Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases Clinica Chimica Acta 2008, 390(1-2):38-43 10.1016/j.cca.2007.12.012
6. Nordestgaard BG Benn M Schnohr P Tybjaerg-Hansen A Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women JAMA 2007, 298(3):299-308 10.1001/ jama.298.3.299 17635890
7. Teno S Uto Y Nagashima H Endoh Y Iwamoto Y Omori Y Takizawa T Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes Diabetes Care 2000, 23(9):1401-1406 10.2337/diacare.23.9.1401 10977041
8. Valdivielso P Hidalgo A Rioja J Aguilar I Ariza MJ Gonzalez-Alegre T Gonzalez-Santos P Smoking and postprandial triglycerides are associated with vascular disease in patients with type 2 diabetes Atherosclerosis 2007, 194:391-396 10.1016/j.atherosclerosis.2006.08.006 16996523
9. Roza A Shizgal H The Harris Benedict equation reevaluated: Resting energy requirements and the body cell mass Am J Clin Nutr 1984, 40(1):168-182 6741850
10. Jacobson TA Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease Am J Clin Nutr 2008, 87(6):1981S-1990 18541599
11. Park Y Harris WS Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance J Lipid Res 2003, 44(3):455-463 10.1194/jlr.M200282-JLR200 12562865
12. Harris WS Miller M Tighe AP Davidson MH Schaefer EJ Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives [abstract] Atherosclerosis 2008, 197:12-24 10.1016/ j.atherosclerosis.2007.11.008 18160071
13. Boizel R Benhamou P Lardy B Laporte F Foulon T Halimi S Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels Diabetes Care 2000, 23(11):1679-1685 10.2337/diacare.23.11.1679 11092292
14. Davidson MH Stein EA Bays HE Maki KC Doyle RT Shalwitz RA Ballantyne CM Ginsberg HN Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study Clin Ther 2007, 29(7):1354-1367 10.1016/j.clinthera.2007.07.018 17825687
15. Phillips M Pullinger C Kroes I Kroes J Hardman D Chen G Curtiss L Gutierrez M Kane J Schumaker V A single copy of apolipoprotein B-48 is present on the human chylomicron remnant J Lipid Res 1997, 38(6):1170-1177 9215545
16. Smith Watts Dane-Stewart Mamo Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state Eur J Clin Invest 1999, 29(3):204-209 10.1046/ j.1365-2362.1999.00431.x 10202376
17. Hayashi T Hirano T Taira T Tokuno A Mori Y Koba S Adachi M Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease [abstract] Atherosclerosis 2008, 197:154-158 10.1016/ j.atherosclerosis.2007.03.015 17462654
18. Lamon-Fava S Diffenderfer MR Barrett PHR Buchsbaum A Matthan NR Lichtenstein AH Dolnikowski GG Horvath K Asztalos BF Zago V Schaefer EJ Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism J Lipid Res 2007, 48(8):1746-1753 10.1194/jlr.M700067-JLR200 17526934
19. Hogue J Lamarche B Deshaies Y Tremblay AJ Bergeron J Gagné C Couture P Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia Metabolism 2008, 57(2):246-254 10.1016/j.metabol.2007.09.008 18191056
20. Yokoyama M Origasa H Matsuzaki M Matsuzawa Y Saito Y Ishikawa Y Oikawa S Sasaki J Hishida H Itakura H Kita T Kitabatake A Nakaya N Sakata T Shimada K Shirato K Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis The Lancet 369(9567):1090-1098 10.1016/S0140-6736(07)60527-3
21. Levy E Spahis S Ziv E Marette A Elchebly M Lambert M Delvin E Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: Impact of dietary n-3 fatty acids Diabetologia 2006, 49(8):1937-1945 10.1007/s00125-006-0315-3 16788801
22. Duez H Lamarche B Uffelman KD Valero R Cohn JS Lewis GF Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans Arterioscler Thromb Vasc Biol 2006, 26(6):1357-63 10.1161/01.ATV.0000222015.76038.14 16614317
23. Hogue J Lamarche B Tremblay AJ Bergeron J Gagne C Couture P Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes J Lipid Res 2007, 48(6):1336-1342 10.1194/ jlr.M600548-JLR200 17337758